Prevention and treatment of HIV/AIDS among drug-using populations: a global perspective

Elizabeth Y Lambert et al. J Acquir Immune Defic Syndr. 2010 Dec.

. 2010 Dec;55 Suppl 1(Suppl 1):S1-4.

doi: 10.1097/QAI.0b013e3181f9c120.

No abstract available

References

1. Montaner J, Lima V, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: A population-based study. Lancet. 2010;376(9740):532–539. - PMC - PubMed
1. Des Jarlais D, Arasteh K, Perlis T, et al. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS. 2007;21:231–235. - PubMed
1. Plankey M, Ostrow D, Stall R, et al. The relationship between methamphetamine and popper use and risk for HIV seroconversion in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2007;45:85–92. - PMC - PubMed
1. Ostrow D, Plankey M, Cox C, et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J Acquir Immune Defic Syndr. 2009;51:349–355. - PMC - PubMed
1. Montaner J, Wood E, Kerr T, et al. Expanded highly active antiretroviral therapy coverage among HIV positive drug users to improve individual and public health outcomes. J Acquir Immune Defic Syndr. 2010 xx (Suppl X): Sxx-Sxx. - PubMed